BioWorld

June 17, 2002

FDA Asks Biogen To Clarify Info On Amevive, But No Trial Needed

The FDA's positive feedback on Biogen Inc.'s Amevive application likely will be the first in a series of key events expected to drive the biotechnology industry this year, an analyst said.(BioWorld Today) Read More

SciClone Gets $10.6M 'Insurance' Financing To Advance Zadaxin

Air Strikes, Not Ground Attacks, To Destroy Immune Cytokines Of Lethal Graft-Versus-Host Disease

Abbott Reports Positive Data From Anti-TNF RA Antibody

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 13, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...